STAT February 13, 2025
Adam Feuerstein

Plus: CRISPR’d medicines are a lousy business

I apologize for this depressing, cynical newsletter. I still hope you read it.

Why it’s so bleak out there

My recent conversations with folks in the biotech investing world can...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article